BridgeBio Oncology Therapeutics (BBOT) stock
BBOT's Quality Score fell 1 point on Tue, Oct 6, to -8. Its volume picked back up.
Follow BBOT's trial news. Pro members can get an alert when BridgeBio Oncology Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Holding it back
59.5% more shares than a year ago.
3 more reasons behind BBOT's -8, for Pro members
What's next for BBOT, and how long its cash lasts
From BridgeBio Oncology Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 9 quarters
Dilution on the horizon
- Shelf registration (S-3, filed Sep 1, 2026)
- At-the-market share sales program (S-3, filed Sep 1, 2026)
Insiders
No open-market buys or sales by its officers or directors in their filings of the last year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 23 daysINOInovio Pharmaceuticals
INOINO-3107
- In 34 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 46 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 57% in 3 months, 50% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 15% over the same 3 months.
−2Long-term trend below a falling 200-day average, down over one year
4 more things pulling BBOT's score down, for Pro members
Why BBOT lags the market
Down 72% in a year while the S&P 500 rose 17%.
Its share count rose 59.5% in a year, so each share is a smaller slice of the company.
1 more reason, the timeline, and the peer table, for Pro members
What's next
Expected to report Wed Nov 11, after the close
After its last 4 reports it closed +1.3% on average, higher 2 of 4 times.
What would turn BBOT's score around: 8 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Nothing is firing on BBOT right now
One per group is shown here.
Also on the chart
- RSI 1418.1
- MACD (12, 26, 9)Above signal
- 50-day average$7.16
- 200-day average$8.98
- ADX 1455.2
- Resistance$8.10
- Bollinger Bands (20, 2)Inside
- Volume0.8x
How BBOT ranks in Biotech
BBOT is #301 of 308 by Quality Score. The top three are shown with their scores, and more by name.
KNSA6/1419
ONC6/1418
EXEL6/1416
AXSMOpen for its score
BBIOOpen for its score
BCRXOpen for its score
BCYCOpen for its score
BBOT0/14-8
When does BBOT report earnings, and what happens after?
Expected to report Wed Nov 11, after the close (in 35 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 11, 2026After close | After close | -1.4% | +2.4% | -2.7% |
| May 12, 2026After close | After close | -1.7% | -0.6% | +7.3% |
| Mar 5, 2026After close | After close | +5.7% | +5.4% | -7.7% |
| Nov 12, 2025After close | After close | +0.4% | -2.0% | +0.4% |
BBOT's officers and directors
Officers and directors with a Form 4 here in the last 3 months. Open one for their trades at every company.
About BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of BBOT's score, with the points and the reason
- All 14 checks on BBOT and on all 3,283 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on BBOT
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.